Breathing Training for Cognitive Impairment
Trial Summary
What is the purpose of this trial?
A recently completed study suggested that processing speed and attention (PS/A) oriented cognitive training (VSOP) produced robust effect on PS/A and working memory, but not in cognitive control or episodic memory, and long-term effects were overall modest. The proposed R01 renewal proposes to identify additional attributes to further enhance transferred and long-term effects of PS/A training in older adults with amnestic mild cognitive impairment (MCI) by addressing adaptation capacity that underpins adaptive learning and neuroplasticity. The goal of the stage II double-blinded randomized trial is to test whether adding resonance frequency breathing (RFB) training to VSOP will strengthen multiple contributors to adaptation capacity, particularly the central and peripheral pathways of autonomic nervous system (ANS) flexibility, which will strengthen VSOP training effect on cognitive and brain function and slow the progress of dementia in MCI. The central hypothesis is that strengthening adaptation capacity, via improving autonomic nervous system (ANS) flexibility, will enhance neuroplasticity and slow progress of dementia in MCI, since adaptation capacity is critical for neuroplasticity of VSOP, but compromised in neurodegenerative process. Older adults with MCI (n = 114) will be randomly assigned to an 8-week combined intervention (RFB+VSOP), VSOP with guided imagery relaxation (IR) control, and a waitlist IR control, with periodical booster training sessions at follow-ups. Mechanistic and distal outcomes include ANS flexibility and multiple markers of dementia progress. Data will be collected across a 14-month period. The two primary aims are to examine long-term effects of the combined intervention on ANS flexibility (Aim 1), as well as the cognitive, behavioral, and functional capacity (Aim 2). The exploratory aim will be to determine the preliminary long-term effect of the combined intervention on neurodegeneration. This can be a reasonable renewal plan from the completed study, aiming to identify additional attributes to further enhance transferred and long-term effects of cognitive training in MCI. This will be among the first randomized controlled trials to examine a novel, combined intervention targeting adaptation capacity in MCI, with an ultimate goal for slowing neurodegeneration. In addition, research on how to monitor adherence - the extent to which VSOP training is delivered and followed as intended - has been conceptually and methodologically limited. Robust monitoring of adherence to cognitive training requires valid assessment of effective engagement. Here, we apply our well-supported, novel framework of mental fatigability for measuring effective engagement in cognitive training. Mental fatigability, the failure to remain engaged in tasks requiring sustained mental effort, can be captured via measures of self-reported disengagement, increase in reaction time during tasks, and facial expression of negative valence/low arousal. These markers of disengagement relate to ventromedial prefrontal cortex dysfunction. We will apply this framework to advance understanding of the underpinnings of adherence to VSOP training by monitoring the extent of effective engagement while using the training platform.
Will I have to stop taking my current medications?
The trial requires that if you are on Alzheimer's disease medication, antidepressants, anxiolytics, or medications for vascular risk or diseases, your dose should be stable for 3 months before joining. You don't need to stop these medications, but you should not change the dose during this period.
What data supports the effectiveness of the treatment Breathing Training for Cognitive Impairment?
Is breathing training safe for humans?
How does the treatment RFB, VSOP differ from other treatments for cognitive impairment?
Eligibility Criteria
This trial is for older adults aged 60-89 with mild cognitive impairment due to Alzheimer's, who score within a specific range on cognitive assessments and can handle daily activities. They must be stable on certain medications if taken, speak English, have good vision and hearing for app use, and not have major cardiovascular diseases or other disqualifying conditions.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive an 8-week combined intervention of RFB+VSOP or control interventions with periodical booster training sessions
Follow-up
Participants are monitored for long-term effects on ANS flexibility and cognitive function
Booster Sessions
Periodical booster training sessions to reinforce treatment effects
Treatment Details
Interventions
- IR
- RFB
- VSOP
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Rochester
Lead Sponsor
National Institute of Nursing Research (NINR)
Collaborator
Stanford University
Collaborator